Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 June;55(2) > Panminerva Medica 2013 June;55(2):109-20

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

  CUTTING EDGE RESPIRATORY MEDICINE 2013


Panminerva Medica 2013 June;55(2):109-20

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

An update on idiopathic pulmonary fibrosis

Margaritopoulos G. A., Giannarakis I., Siafakas N. M., Antoniou K. M.

Interstitial Lung Disease Unit, University Hospital of Heraklion, Crete, Greece


PDF  


Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease with a median survival of 3-5 years. Despite recent advances the pathophysiology of the disease remains not fully understood. However, injury of type II alveolar epithelial cells is considered the key event for the initiation of the development of fibrosis. An accurate diagnosis is imperative because commencing treatment at an early stage may reduce disease progression. In this regard, the multidisciplinary disease meeting between pulmonologists, radiologists and pathologists has definitely improved the diagnostic confidence. Importantly, a milestone has been recently reached as the first IPF-specific drug namely pirfenidone has been licensed in Europe, Japan and Asia.

top of page

Publication History

Cite this article as

Corresponding author e-mail

gmargaritop@yahoo.gr